Wolverine Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $198K | Sell |
9,100
-10,500
| -54% | -$203K | ﹤0.01% | 1087 |
|
|
2025
Q4 | $422K | Sell |
19,600
-19,100
| -49% | -$403K | ﹤0.01% | 968 |
|
|
2025
Q3 | $746K | Sell |
38,700
-25,000
| -39% | -$446K | 0.01% | 800 |
|
|
2025
Q2 | $1.09M | Buy |
63,700
+38,500
| +153% | +$1.64M | 0.01% | 688 |
|
|
2025
Q1 | $1.61M | Sell |
25,200
-100
| -0.4% | -$10.5K | 0.02% | 570 |
|
|
2024
Q4 | $3.08M | Hold |
25,300
| – | – | 0.03% | 415 |
|
|
2024
Q3 | $3.16M | Hold |
25,300
| – | – | 0.03% | 392 |
|
|
2024
Q2 | $4M | Hold |
25,300
| – | – | 0.05% | 333 |
|
|
2024
Q1 | $3.28M | Sell |
25,300
-106,900
| -81% | -$13.1M | 0.04% | 379 |
|
|
2023
Q4 | $12.7M | Buy |
132,200
+200
| +0.2% | +$19.2K | 0.11% | 199 |
|
|
2023
Q3 | $16M | Buy |
132,000
+131,900
| +131,900% | +$14.9M | 0.18% | 141 |
|
|
2023
Q2 | $11.5K | Buy |
+100
| New | +$12.9K | ﹤0.01% | 1374 |
|
|
2023
Q1 | – | Sell |
-116,800
| Closed | -$15.1M | – | 2073 |
|
|
2022
Q4 | $15.1M | Hold |
116,800
| – | – | 0.16% | 161 |
|
|
2022
Q3 | $12.9M | Hold |
116,800
| – | – | 0.14% | 171 |
|
|
2022
Q2 | $8.76M | Sell |
116,800
-100,000
| -46% | -$7.36M | 0.09% | 241 |
|
|
2022
Q1 | $16.9M | Sell |
216,800
-29,400
| -12% | -$2.25M | 0.17% | 145 |
|
|
2021
Q4 | $22.2M | Buy |
246,200
+20,800
| +9% | +$1.78M | 0.21% | 128 |
|
|
2021
Q3 | $20.8M | Buy |
225,400
+113,000
| +101% | +$8.7M | 0.18% | 145 |
|
|
2021
Q2 | $8.74M | Buy |
112,400
+106,900
| +1,944% | +$8.1M | 0.07% | 211 |
|
|
2021
Q1 | $409K | Sell |
5,500
-14,100
| -72% | -$1.3M | ﹤0.01% | 984 |
|
|
2020
Q4 | $3.34M | Buy |
19,600
+3,200
| +20% | +$474K | 0.02% | 320 |
|
|
2020
Q3 | $2.3M | Buy |
16,400
+1,400
| +9% | +$213K | 0.02% | 376 |
|
|
2020
Q2 | $2.4M | Hold |
15,000
| – | – | 0.02% | 354 |
|
|
2020
Q1 | $1.47M | Sell |
15,000
-13,200
| -47% | -$1.51M | 0.02% | 416 |
|
|
2019
Q4 | $3.64M | Sell |
28,200
-4,400
| -13% | -$444K | 0.04% | 316 |
|
|
2019
Q3 | $2.46M | Buy |
32,600
+14,500
| +80% | +$1.71M | 0.03% | 368 |
|
|
2019
Q2 | $2.75M | Buy |
18,100
+13,700
| +311% | +$1.67M | 0.04% | 363 |
|
|
2019
Q1 | $524K | Buy |
4,400
+1,300
| +42% | +$167K | 0.01% | 833 |
|
|
2018
Q4 | $338K | Hold |
3,100
| – | – | ﹤0.01% | 1134 |
|
|
2018
Q3 | $500K | Hold |
3,100
| – | – | 0.01% | 1017 |
|
|
2018
Q2 | $409K | Buy |
+3,100
| New | +$292K | 0.01% | 988 |
|
|
2014
Q2 | – | Sell |
-300
| Closed | -$268K | – | 2531 |
|
|
2014
Q1 | $268K | Buy |
300
+200
| +200% | +$5.1K | 0.01% | 781 |
|
|
2013
Q4 | $155K | Buy |
+100
| New | +$2.97K | ﹤0.01% | 1274 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Wolverine Asset Management's SRPT Position: Q1 2026 in Review
Wolverine Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 65% in Q1 2026, selling an estimated $180K and leaving 4,920 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1169.
Wolverine Asset Management first reported a position in SRPT in Q4 2013 and has held it in 13 quarters since. The position peaked at $805K in Q1 2014. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Wolverine Asset Management held 4,920 shares of Sarepta Therapeutics worth $107K as of Q1 2026.
- Wolverine Asset Management sold 9,317 Sarepta Therapeutics shares in Q1 2026, an estimated $180K.
- Sarepta Therapeutics made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1169 holding.
- Wolverine Asset Management first reported a position in Sarepta Therapeutics in Q4 2013 and has held it in 13 quarters since.
- Wolverine Asset Management's Sarepta Therapeutics position peaked at $805K in Q1 2014.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.